Healthcare provider profile · identity verified

Daria Chacon, MD

Internal Medicine · PHILADELPHIA, PA · NPI 1275735672

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	117	25
Atorvastatin Calcium	Atorvastatin Calcium	112	26
Omeprazole	Omeprazole	101	21
Albuterol Sulfate Hfa	Albuterol Sulfate	86	14
Metformin Hcl	Metformin Hcl	71	19
Levothyroxine Sodium	Levothyroxine Sodium	66	11
Fluticasone Propionate	Fluticasone Propionate	64	suppressed
Losartan Potassium	Losartan Potassium	62	11
Alcohol Prep Pads	Alcohol Antiseptic Pads	60	13
Chlorthalidone	Chlorthalidone	58	11
Metoprolol Succinate	Metoprolol Succinate	57	14
Pantoprazole Sodium	Pantoprazole Sodium	54	suppressed
Amlodipine Besylate	Amlodipine Besylate	53	15
Ibuprofen	Ibuprofen	49	12
Jardiance	Empagliflozin	48	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	12
Famotidine	Famotidine	47	suppressed
Lisinopril	Lisinopril	43	14
Potassium Chloride	Potassium Chloride	39	suppressed
Trulicity	Dulaglutide	39	suppressed
Diclofenac Sodium	Diclofenac Sodium	34	11
Hydrochlorothiazide	Hydrochlorothiazide	34	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	32	suppressed
Simvastatin	Simvastatin	30	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Spironolactone	Spironolactone	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	24	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Labetalol Hcl	Labetalol Hcl	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Montelukast Sodium	Montelukast Sodium	20	suppressed
Naproxen	Naproxen	20	suppressed
Arnuity Ellipta	Fluticasone Furoate	19	suppressed
Furosemide	Furosemide	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	18	suppressed
Junel	Norethindrone Ac/Eth Estradiol	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Glimepiride	Glimepiride	17	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Eliquis	Apixaban	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Ibu	Ibuprofen	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Tiotropium Bromide	Tiotropium Bromide	14	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Colchicine	Colchicine	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Topiramate	Topiramate	13	suppressed
Trazodone Hcl	Trazodone Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Clotrimazole	Clotrimazole	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error